Topoisomerase I Inhibitor Evodiamine Acts As an Antibacterial Agent against Drug-Resistant Klebsiella pneumoniae

Abstract

Topoisomerase inhibitors have been developed in a variety of clinical applications. We investigated the inhibitory effect of evodiamine on E. coli topoisomerase I, which may lead to an anti-bacterial effect. Evodiamine inhibits the supercoiled plasmid DNA relaxation that is catalyzed by E. coli topoisomerase I, and computer-aided docking has shown that the Arg161 and Asp551 residues of topoisomerase I interact with evodiamine. We investigated the bactericidal effect of evodiamine against multidrug-resistant Klebsiella pneumoniae. Evodiamine showed a significantly lower minimal inhibitory concentration value (MIC 128 µg/mL) compared with antibiotics (> 512 µg/mL) against the clinical isolate of K. pneumoniae. The results suggested that evodiamine is a potential agent against drug-resistant bacteria.

Key words

antibiotic - drug resistance - evodiamine - K. pneumonia - zopoisomerase

^* These authors contributed equally to this work.

• References

• 1 Rapp RP, Urban C. Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns. Pharmacotherapy 2012; 32: 399-407
• 2 Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother 2009; 53: 2227-2238
• 3 Manageiro V, Ferreira E, Cougnoux A, Albuquerque L, Canica M, Bonnet R. Characterization of the inhibitor-resistant SHV beta-lactamase SHV-107 in a clinical Klebsiella pneumoniae strain coproducing GES-7 enzyme. Antimicrob Agents Chemother 2012; 56: 1042-1046
• 4 Walsh TR, Toleman MA, Jones RN. Comment on: Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2007; 59: 799-800 author reply 800–801
• 5 Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602
• 6 Teicher BA. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies. Biochem Pharmacol 2008; 75: 1262-1271
• 7 Wethington SL, Wright JD, Herzog TJ. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert Rev Anticancer Ther 2008; 8: 819-831
• 8 Masse E, Drolet M. Relaxation of transcription-induced negative supercoiling is an essential function of Escherichia coli DNA topoisomerase I. J Biol Chem 1999; 274: 16654-16658
• 9 Rui S, Tse-Dinh YC. Topoisomerase function during bacterial responses to environmental challenge. Front Biosci 2003; 8: d256-d263
• 10 Tse-Dinh YC. Bacterial topoisomerase I as a target for discovery of antibacterial compounds. Nucleic Acids Res 2009; 37: 731-737
• 11 Cheng B, Liu IF, Tse-Dinh YC. Compounds with antibacterial activity that enhance DNA cleavage by bacterial DNA topoisomerase I. J Antimicrob Chemother 2007; 59: 640-645
• 12 Jiang J, Hu C. Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa . Molecules 2009; 14: 1852-1859
• 13 Chan AL, Chang WS, Chen LM, Lee CM, Chen CE, Lin CM, Hwang J. Evodiamine stabilizes topoisomerase I-DNA cleavable complex to inhibit topoisomerase I activity. Molecules 2009; 14: 1342-1352
• 14 Pan X, Hartley JM, Hartley JA, White KN, Wang Z, Bligh SW. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells. Phytomedicine 2012; 19: 618-624
• 15 Bugreev DV, Nevinsky GA. Structure and mechanism of action of type IA DNA topoisomerases. Biochemistry (Mosc) 2009; 74: 1467-1481
• 16 Zhu CX, Roche CJ, Papanicolaou N, DiPietrantonio A, Tse-Dinh YC. Site-directed mutagenesis of conserved aspartates, glutamates and arginines in the active site region of Escherichia coli DNA topoisomerase I. J Biol Chem 1998; 273: 8783-8789
• 17 Narula G, Annamalai T, Aedo S, Cheng B, Sorokin E, Wong A, Tse-Dinh YC. The strictly conserved Arg-321 residue in the active site of Escherichia coli topoisomerase I plays a critical role in DNA rejoining. J Biol Chem 2011; 286: 18673-18680
• 18 Lim KT, Yeo CC, Yasin RM, Balan G, Thong KL. Characterization of multidrug-resistant and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strains from Malaysian hospitals. J Med Microbiol 2009; 58: 1463-1469
• 19 Nazir H, Cao S, Hasan F, Hughes D. Can phylogenetic type predict resistance development?. J Antimicrob Chemother 2011; 66: 778-787
• 20 Rahman MM, Gray AI, Khondkar P, Islam MA. Antimicrobial activities of alkaloids and lignans from Zanthoxylum budrunga . Nat Prod Commun 2008; 3: 45-47
• 21 Xu X, Leng F. A rapid procedure to purify Escherichia coli DNA topoisomerase I. Protein Expr Purif 2011; 77: 214-219
• 22 Feinberg H, Changela A, Mondragon A. Protein-nucleotide interactions in E. coli DNA topoisomerase I. Nat Struct Biol 1999; 6: 961-968
• 23 Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267: 727-748
• 24 National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 6th edition, Vol. 23. Wayne: NCCLS Documents M7-A6; 2003
• 25 Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res 1991; 19: 6823-6831
• 26 Fang H, Ataker F, Hedin G, Dornbusch K. Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006. J Clin Microbiol 2008; 46: 707-712